Profound Medical Corp.

Profound Medical Corp. is a commercial-stage medical device company developing incision-free therapeutic systems that use image-guided ablation to treat diseased tissue. The company operates through two primary product lines: TULSA-PRO, which combines MRI imaging with robotically controlled transurethral ultrasound and temperature feedback to ablate prostate tissue for malignant and benign conditions, and Sonalleve, which integrates real-time MRI with thermal imaging for treating uterine fibroids, adenomyosis, bone metastases, osteoid osteoma, and other benign tumors.

The company generates revenue from both products, though specific segment breakdowns are not disclosed. TULSA-PRO represents the lead revenue driver for the company's commercial operations. Sonalleve contributes additional revenue streams across multiple therapeutic indications, primarily in Europe and North America.

Profound Medical operates with approximately 142 full-time employees and maintains its headquarters in Mississauga, Ontario. The company has established market presence across Canada, the United States, Germany, and Finland, with commercialization efforts ongoing in these geographies. The company is listed on Nasdaq and incorporated under Ontario law.